However, this model is likely to trigger qualitatively and quantitatively different mediators of tissue damage compared to the compartmentalized inflammation as is seen in progressive MS, and may therefore not address a similar biological role of DYSF in progressive MS. This evidence concerns the gene DYSF and myeloid sarcoma.